Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct;63(10):e231-e239.
doi: 10.1111/ijd.17409. Epub 2024 Aug 7.

Predictors of initiating biologics in the treatment of psoriasis

Emilia Linnemann  1 , Mia-Louise Nielsen  2 , Lara Valeska Maul  3 , Clara Richter  3 , Isabella Dommann  3 , Alexander Zink  4 , Christoph Schlapbach  5 , Nikhil Yawalkar  5 , Curdin Conrad  6 , Antonio Cozzio  7 , Thomas Kündig  4   8 , Alexander Navarini  9 , Alexander Egeberg  2   10 , Julia-Tatjana Maul  3   8
Affiliations

Predictors of initiating biologics in the treatment of psoriasis

Emilia Linnemann et al. Int J Dermatol. 2024 Oct.

Abstract

Background: Biologics are among the most effective therapies for psoriasis. However, many patients are only introduced to them at advanced stages of the disease course.

Objectives: Our aim was to identify predictors of initiating biologic therapy in patients with psoriasis and compare patients initiating biologics early versus late in their disease course.

Methods: Kaplan-Meier curves visualized time to biologic initiation, while Cox regression models further explored variables as predictors of biologic initiation. Mann-Whitney U and chi-squared tests compared patients who started biologics early with those who began biologics later in the disease course.

Results: Our primary analysis included 233 psoriasis patients. Cox regression showed that age at diagnosis (P = 0.007), general physical well-being (P = 0.02), and nail psoriasis severity (P = 0.02) were significantly associated with time to biologic initiation. Our secondary analysis, the comparisons between patients starting biologics early versus later in the disease course, included a total of 378 patients. The median (interquartile range [IQR]) age at diagnosis was 34.5 (25.0-51.2) years for patients initiating biologics within 5 years, compared to 22.0 (15.0-32.8) years for patients initiating biologics later (P < 0.0001). The median (IQR) age at initiation was 37.0 (27.0-53.2) and 45.0 (36.0-55.0) years for patients initiating biologics earlier versus later than 5 years (P = 0.04).

Conclusions: Age at diagnosis, general well-being, and severity of nail psoriasis significantly predicted future initiation of biologic treatment. Patients initiating biologics early in their disease course were generally older at diagnosis but younger at the time of biologic initiation compared to patients initiating biologics later in their disease course.

Keywords: biologics; cox regression; predictors; psoriasis; registries; treatment.

PubMed Disclaimer

References

    1. Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377–385.
    1. Menter A, Griffiths CE. Current and future management of psoriasis. Lancet. 2007;370:272–284.
    1. Nast A, Smith C, Spuls PI, Avila Valle G, Bata‐Csörgö Z, Boonen H, et al. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris—part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34:2461–2498.
    1. Nast A, Smith C, Spuls PI, Avila Valle G, Bata‐Csörgö Z, Boonen H, et al. EuroGuiDerm guideline on the systemic treatment of Psoriasis vulgaris—part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol. 2021;35:281–317.
    1. Maul J‐T, Djamei V, Kolios AGA, Meier B, Czernielewski J, Jungo P, et al. Efficacy and survival of systemic psoriasis treatments: an analysis of the swiss registry SDNTT. Dermatology. 2016;232:640–647.

LinkOut - more resources